Medical News

RSS

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients.

23 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

A new study presented today at The International Liver Congress 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments.

23 Apr 2015

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes.

23 Apr 2015

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Many countries in the World Health Organization European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Transportable MP Airdrive device enhances donor liver viability for transplantation

A new device has demonstrated it has the potential to enhance the viability of donor livers for transplantation. Results revealed today at The International Liver Congress 2015 show that the transportable machine perfusion (MP) Airdrive is able to effectively maintain the quality of livers derived from donation after circulatory death (DCD).

23 Apr 2015

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver Congress 2015 has shown the devastating impact the infection has on their daily lives.

23 Apr 2015

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Data revealed today at The International Liver Congress 2015 show that non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).

23 Apr 2015

Study supports use of vitamin E as effective treatment for NASH

Results revealed today at The International Liver Congress 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis.

23 Apr 2015

Novel immunotherapeutic shows promise against chronic hepatitis B

A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Civacir can effectively prevent HCV recurrence following liver transplants

New data from an ongoing Phase III trial revealed today at The International Liver Congress 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT).

23 Apr 2015

Physical forces can affect development of limbs in embryos

University of Toronto engineers and a pediatric surgeon have joined forces to discover that physical forces like pressure and tension affect the development of limbs in embryos--research that could someday be used to help prevent birth defects.

23 Apr 2015

Children exposed to adverse childhood experience more likely to develop asthma

Robyn Wing, M.D., an emergency medicine physician at Hasbro Children's Hospital, recently led a study that found children who were exposed to an adverse childhood experience (ACE) were 28 percent more likely to develop asthma.

23 Apr 2015

WPI researchers receive NIH grant to develop new class of tissue-engineered heart valves

With a $450,000 grant from the National Institutes of Health, researchers at Worcester Polytechnic Institute will analyze how mechanical forces and cellular growth factors affect the growth and development of human heart valves to advance the long-term goal of using tissue engineering to develop replacement valves that are more natural and longer-lasting than current replacement valves.

23 Apr 2015

Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Mylan N.V. today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Sofosbuvir 400 mg tablets under the brand name MyHep in India.

23 Apr 2015

Study: Demanding jobs raise survival chances in frontotemporal dementia

People with more demanding jobs may live longer after developing the disease frontotemporal dementia than people with less skilled jobs, according to a new study published in the April 22, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

23 Apr 2015

Gulf Coast residents continue to struggle with the aftermath of Deepwater Horizon oil spill

Five years ago, on April 20, 2010, the BP Deepwater Horizon oil platform exploded; over the next five months, more than 206 million gallons of oil gushed into the Gulf of Mexico, affecting more than 950 miles of shoreline.

23 Apr 2015

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

In a paper published in the New England Journal of Medicine, the scientists show that a positron-emission tomography (PET) scan immediately after treatment with chemotherapy can identify patients who have a very good outcome without additional radiotherapy.

23 Apr 2015

Medical News

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Study calls for better surveillance to prevent spread of viral hepatitis in WHO European Region

Transportable MP Airdrive device enhances donor liver viability for transplantation

Survey: Nearly half of people infected with viral hepatitis suffer discrimination

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Study supports use of vitamin E as effective treatment for NASH

Novel immunotherapeutic shows promise against chronic hepatitis B

Civacir can effectively prevent HCV recurrence following liver transplants

Physical forces can affect development of limbs in embryos

Children exposed to adverse childhood experience more likely to develop asthma

WPI researchers receive NIH grant to develop new class of tissue-engineered heart valves

Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Study: Demanding jobs raise survival chances in frontotemporal dementia

Gulf Coast residents continue to struggle with the aftermath of Deepwater Horizon oil spill

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News